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Abstract
Objectives
Indoleamine 2,3-dioxygenase-1 (IDO1) is an immune-modulatory enzyme that catalyzes
the degradation of tryptophan (Trp) to kynurenine (Kyn) and is strongly induced by inter-
feron (IFN)-γ. We previously reported highly increased levels of IFN-γ and corresponding
IDO activity in patients with hemophagocytic lymphohistiocytosis (HLH), a hyper-inflamma-
tory syndrome. On the other hand, IFN-γ and IDO were low in patients with systemic juve-
nile idiopathic arthritis (sJIA), an autoinflammatory syndrome. As HLH can occur as a
complication of sJIA, the opposing levels of both IFN-γ and IDO are remarkable. In animal
models for sJIA and HLH, the role of IFN-γ differs from being protective to pathogenic. In
this study, we aimed to unravel the role of IDO1 in the pathogenesis of sJIA and HLH.
Methods
Wild-type and IDO1-knockout (IDO1-KO) mice were used in 3 models of sJIA or HLH: com-
plete Freund’s adjuvant (CFA)-injected mice developed an sJIA-like syndrome and second-
ary HLH (sHLH) was evoked by either repeated injection of unmethylated CpG
oligonucleotide or by primary infection with mouse cytomegalovirus (MCMV). An anti-CD3-
induced cytokine release syndrome was used as a non-sJIA/HLH control model.
Results
No differences were found in clinical, laboratory and hematological features of sJIA/HLH
between wild-type and IDO1-KO mice. As IDO modulates the immune response via induc-
tion of regulatory T cells and inhibition of T cell proliferation, we investigated both features in
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a T cell-triggered cytokine release syndrome. Again, no differences were observed in
serum cytokine levels, percentages of regulatory T cells, nor of proliferating or apoptotic thy-
mocytes and lymph node cells.
Conclusions
Our data demonstrate that IDO1 deficiency does not affect inflammation in sJIA, sHLH and
a T cell-triggered cytokine release model. We hypothesize that other tryptophan-cataboliz-
ing enzymes like IDO2 and tryptophan 2,3-dioxygenase (TDO) might compensate for the
lack of IDO1.
Introduction
Indoleamine 2,3-dioxygenase (IDO) is an immune-modulatory enzyme catalyzing the rate-
limiting step in the degradation of the essential amino acid tryptophan (Trp) to kynurenine
(Kyn) [1,2]. It exerts its immune-regulating functions by several means. A local depletion of
Trp increases levels of uncharged transfer RNA thereby activating the amino-acid sensitive
GCN2 stress-kinase pathway leading to cell cycle arrest or anergy in T cells [3]. Amino acid
deficiency might further inhibit the mammalian target of rapamycin (mTOR) pathway, leading
to a translational block [4]. On the other hand, increase of Kyn and other Trp metabolites act
as immunologically active ligands of the aryl hydrocarbon receptor (AhR) and can as well
induce cell cycle arrest, apoptosis and favor the development of regulatory T cells (Treg) [5,6].
Next to its enzymatic function, IDO was reported to act as an intracellular signaling molecule
in IDO-expressing dendritic cells [7].
The IDO pathway is involved in multiple immunological processes: first Trp degradation
was described to be an innate response against infections. Later on, IDO was reported to take
part in maternal tolerance, to inhibit local inflammation and autoimmunity and to suppress
immune responses to cancer and infections [6]. More recently it was discovered that IDO,
which was renamed IDO1, bears a paralogue, IDO2, with similar enzymatic activity. Next to
IDO, the degradation of Trp can be catalyzed by another enzyme, tryptophan 2,3-dioxygenase
(TDO). TDO is mainly expressed in the liver and is believed to have a homeostatic role in con-
trolling basal Trp levels. IDO1 on the other hand is expressed in most tissues and can be
induced by interferons (IFNs), in particular IFN-γ, and LPS [1,2,8].
Systemic juvenile idiopathic arthritis (sJIA) is a complex autoinflammatory syndrome in
children presenting with arthritis, fever, rash and/or lymphadenopathy [9]. About 10% of sJIA
patients can develop a potentially fatal complication called macrophage activation syndrome
(MAS), a term that refers to excessive activation of macrophages [10]. Up to 50% of sJIA
patients already present with subclinical or occult MAS as evident from increased plasma levels
of soluble CD163 (sCD163) and soluble CD25 (sCD25) and the presence of hemophagocytic
macrophages in their bone marrow [11,12]. MAS is classified as a secondary form of hemopha-
gocytic lymphohistiocytosis (HLH). Primary HLH has a genetic base, while secondary or reac-
tive HLH (sHLH) develops in the context of malignancies, infections and inflammatory
disorders, in the latter case it is called MAS [13]. Nevertheless, a significant percentage of
sHLH patients, including those with underlying sJIA, present with HLH-associated gene
defects [14,15]. Both sJIA and sHLH are characterized by the development of a cytokine storm,
with important roles for IL-1β, IL-6 and IL-18 [16,17]. In sJIA patients, it has been demon-
strated that high levels of IL-6 are correlated with the occurrence of arthritis, while IL-18 is
IDO1 in Mouse Models of sJIA and sHLH
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associated with the development of sHLH (MAS) in sJIA patients [18]. The role of IFN-γ in
sJIA and HLH/MAS is not clear: in animal models it differs from being protective to patho-
genic (reviewed in Avau and Matthys and in Brisse et al. [13,19]). In patients, we recently
investigated the potential role of IFN-γ by analyzing plasma levels of IFN-γ as well as IFN-γ-
induced proteins [20]. To investigate IFN-γ-induced IDO activity, the ratio of Kyn to Trp was
measured in plasma of sJIA and HLH/MAS patients. Similarly to levels of IFN-γ, we detected a
rather low IDO activity in sJIA and a more pronounced activity in HLH/MAS patients.
The cause of excessive inflammation as seen in sJIA and sHLH is not completely under-
stood, but one of the hypotheses is that the disease results from a defective downregulation of
an immune response to an unknown trigger [16,21]. Therefore, research into the role of
inflammation-tempering pathways such as IDO1, might provide further insight into the patho-
genesis. Based on our previous study where we reported a rather low IFN-γ profile in sJIA
patients [20], together with the disease-limiting role of IFN-γ in an sJIA mouse model [22], we
believe IFN-γ plays a protective role in sJIA. Too low levels of IFN-γ (and consequently IDO1)
might therefore instigate the inflammatory response in these patients. On the other hand, IFN-
γ is believed to be a pathogenic factor in most models of HLH [21]. Nevertheless, IFN-γ-
induced IDO1 might still act to dampen the pathogenic effects of IFN-γ in these patients.
To verify the concept that IDO1 has immune-regulatory activities in sJIA and sHLH, we
investigated the impact of an IDO1-deficient setting in 3 relevant mouse models of sJIA and
sHLH. Since both diseases are characterized by a cytokine storm, the role of IDO1 was also
explored in a model for T cell-triggered cytokine release syndrome. Unexpectedly, in none of
the animal models, symptoms were different in IDO1-KO as compared to WTmice, suggesting
IDO1 does not play a role in sJIA, sHLH or T cell-triggered disease. Although no increased lev-
els of IDO2 and TDO were detected, we hypothesize that even basal levels of these 2 other Trp-
degrading enzymes might compensate for the loss of IDO1 in these mice.
Materials and Methods
Mice and experimental design
Mice were all bred under specific pathogen-free conditions in the Experimental Animal Centre
of Leuven University. Unless stated otherwise, mice ages 6–9 weeks were used and were age-
and sex-matched for grouping within each experiment. Mice were euthanized with Nembutal
(Ceva, Libourne, France). Experiments were approved by the Ethics Committee of the Univer-
sity of Leuven (P034/2013). BALB/c IDO1-KO mice were kindly provided by Muriel Moser
(ULB, Gosselies, Belgium) and were originally described by Mellor et al. [23]. WT and
IDO1-KO littermates from a heterozygous breed were used for CFA immunization and anti-
CD3 treatment. The mouse model of sJIA has recently been described [24]. Briefly, CFA
(Difco, Franklin Lakes, NJ, USA) with added heat-killedMycobacterium butyricum (1.5 mg/
ml) was emulsified in an equal volume of phosphate buffered saline (PBS). 100 μl was injected
subcutaneously at the base of the tail. Mice were euthanized between 21 and 29 days after CFA
injection. To compare symptoms with the original sJIA model, CFA-injected IFN-γ-KO mice,
bred in our animal facility, were included. Non-injected mice were included as controls. To
elicit a cytokine release syndrome, BALB/c WT and IDO1-KO littermates were injected intra-
peritoneally (i.p.) with 75 μg anti-CD3 (kindly provided by Louis Boon, EPIRUS Biopharma-
ceuticals Netherlands BV) in 100 μl PBS or PBS alone [25]. 20 μg anti-CD3 was administered
to analyze cytokine production in serum from eye puncture (4h) or heart puncture (24h).
Blood glucose levels were measured from tail blood at different time points with glucose test
strips (One Touch Vita, Zug, Switzerland). Mice were sacrificed 24h after injection. The
TLR9-triggered sHLH or MAS model has been described by Behrens et al. [26]. For these
IDO1 in Mouse Models of sJIA and sHLH
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experiments mice of the C57BL/6 strain were used (IDO1-KO C57BL/6 mice were provided by
Francesca Fallarino and were originally derived from Jackson Laboratory (Bar Harbor, ME,
USA)). Mice were injected i.p. on days 0, 2, 4, 7, and 9 with 100 μl PBS or 50 μg unmethylated
CpG1826 (IDT, Coraville, IA, USA) in 100 μl PBS to elicit MAS-like disease. As a model for
sHLH, we used a mouse cytomegalovirus (MCMV)-triggered mouse model that was developed
in our laboratory [27]. Hereto, BALB/c WT and IDO1-KO mice were infected with 5x103 PFU
salivary gland-derived MCMV (Smith strain) by i.p. injection at 5 weeks of age to evoke an
sHLH syndrome. Mice were sacrificed at day 5 post-infection.
Blood analysis and flow cytometry
Heparin-anti-coagulated blood samples were obtained by heart puncture (LEO Pharma, Bal-
lerup, Denmark). A complete blood cell analysis was performed with a Cell-Dyn 3700 hematol-
ogy analyzer (Abbott Diagnostics, Abbott Park, IL, USA). For flow cytometry, single cell
suspensions from spleen, inguinal lymph nodes or thymus were incubated with anti-CD16/
anti-CD32 antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany) and stained with the fol-
lowing monoclonal antibodies: FITC-labeled CD3e (145-2C11); PE-labeled CD122 (5H4),
CD4 (L3T4), CD25 (PC61.5) and KI67 (B56); APC-labeled, CD49b (DX5), CD8 (53-6.7) and
FOXP3 (FJK-16s); PerCP-Cy5.5-labeled CD4 (RM4-5) (all from eBioscience, San Diego, CA,
USA; except for KI67 from BD Biosciences, San Jose, CA, USA). Propidium iodide (PI) was
used to exclude dead cells. Staining for active caspase 3 (Casp3) was performed using a Casp3
inhibitor conjugated to FITC, according to the manufacturer’s protocol (Abcam, Cambridge,
UK). Intracellular staining for KI67 and forkhead box P3 (FOXP3) were performed with the
BD cytofix/cytoperm kit (BD Biosciences). Flow cytometric analysis was performed with a
FACSCalibur flow cytometer (BD Biosciences) using FlowLogic analysis software (Inivai Tech-
nologies, Mentone Victoria, Australia).
qPCR, ELISA, Western Blot
Total RNA was extracted using the PureLink RNAMini kit (Invitrogen, Carlsbad, CA, USA).
Complementary DNA was obtained using Superscript II reverse transcriptase and random
primers (Invitrogen). Real-time qPCR was performed by using TaqMan FAST PCRmaster mix
(Applied Biosystems, Foster City, CA, USA) and primer/probe pairs from Integrated DNA
Technologies (IDT, Coralville, IA, USA, Gene Expression Assays: Ido1, Mm.PT.58.29540170;
Ido2, Mm.PT.58.41795494; Tdo2, Mm.PT.58.13890594). Expression levels were normalized to
the expression housekeeping genes Gadph (Mm.PT.39a.1) and/or Gusb (Mm.PT.39a.22214848)
by using a geometric mean normalization method as previously described [28]. Serum cytokines
were measured with a ProcartaPlex multiplex immunoassay (eBioscience). sCD25 levels were
determined according to the manufacturer’s instruction (Duoset, R&D Systems, Minneapolis,
MS, USA) and a sandwich ELISA detecting the heavy chain of ferritin was kindly offered by Dr.
Santambrogio [29]. Plasma concentrations of aspartate transaminase (AST) and alanine trans-
aminase (ALT) were measured spectrophotometrically using a UV-kinetic method according to
the manufacturer’s instructions (ALT (SGPT) Reagent Set, AST (SGOT) Reagent Set, Teco
Diagnostics, Anaheim, CA, USA). Liver and spleen tissue was lysed in PBS with 0.1% Triton
(Panreac AppliChem, Darmstadt, Germany) supplemented with proteinase inhibitor (Roche,
Basel, Switzerland) using a tissue homogenizer (Precellys 24, Bertin Technologies, Montigny-le-
Bretonneux, France). Samples were centrifuged (20 min; 12000g, 4°C) and supernatant was
used for further analysis. Protein concentration was quantified using a bicinchoninic acid (BCA,
Bio-Rad Laboratories, Hercules, CA, USA) assay and samples were subjected to SDS-PAGE.
Western blot analysis of IDO2 and TDO2 was performed as described [30].
IDO1 in Mouse Models of sJIA and sHLH
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Statistical analysis
Data were analyzed by non-parametric Mann-Whitney U test for comparison of 2 groups or
by Kruskal-Wallis test, followed by Dunn’s multiple comparison test for comparison of 3 or
more groups. P-values< 0.05 were considered significant. GraphPad Prism software version
6.00 was used.
Results
IDO1-deficient mice develop a systemic inflammation comparable with
wild-type mice upon challenge with CFA
To investigate the role of IDO1 in a mouse model of sJIA, we injected complete Freund’s adju-
vant (CFA) in WT and IDO1-KO BALB/c mice and compared their disease courses with IFN-
γ-KO mice, in which CFA-elicited symptoms are reminiscent of sJIA [22]. In contrast to IFN-
γ-KO mice, WT and IDO1-KO mice did not show wasting following immunization with CFA
(Figs 1A and 2A). In both CFA-injected WT and IDO1-KO mice, spleen weight did not
increase significantly (Figs 1B and 2B). When analyzing blood counts, we observed no increase
in platelet counts nor neutrophils as was seen in IFN-γ-KO mice (Figs 1C and 2C). Relative
abundances of spleen NK cells were significantly decreased after injection with CFA, however,
there was no difference between IDO1-KO animals and their WT counterparts (Fig 1D).
Fig 1. CFA injection in BALB/cWT and IDO1-KOmice. BALB/c WT and IDO1-KOmice were injected with CFA at day 0. Mice were sacrificed between day
21 and day 29 after immunization. A. Average ± SD percent body weight change. B. Spleen weight as a percentage of total body weight. C. Blood platelet
and neutrophil counts as measured by hematology analyzer. D. Percentage of live CD3- CD49b+ CD122+ natural killer cells of total live spleen cells. B-D:
Symbols represent individual mice with the group median. Representative images of two independent experiments. * p<0.05; Kruskal-Wallis with Dunn’s
post test. NI, noninjected; CFA, complete Freund’s adjuvant; NK, natural killer.
doi:10.1371/journal.pone.0150075.g001
IDO1 in Mouse Models of sJIA and sHLH
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Moreover, NK cell numbers were lower in CFA-injected IFN-γ-KO mice (Fig 2D). Together,
we conclude that IDO1 does not play a role in the systemic inflammation elicited by immuni-
zation of mice with CFA.
IDO1 does not play a role in a TLR9-triggered MASmouse model
We aimed to unravel the role of IDO1 in a TLR9-triggered mouse model of MAS, described by
Behrens et al. [31]. In this model it was shown that IFN-γ-KO mice are protected from disease
[31]. In WT mice, we confirmed the results of Behrens et al. as mice repeatedly injected with
unmethylated CpG oligonucleotide showed increased spleen and liver weight (Fig 3A and 3B)
and decreased numbers of circulating red blood cells, platelets and lymphocytes (Fig 3C–3E).
In contrast to the original report we observed increased levels of white blood cells, neutrophils
and monocytes (Fig 3F–3H). NK cell numbers in spleen were decreased after CpG injection
(Fig 3I). Similar results were found in IDO1-KO mice upon CpG injection, suggesting IDO1 is
neither necessary nor protective in a TLR9-triggered MAS model.
IDO1 does not influence disease in a MCMV-infected secondary HLH
mouse model
As IFNs play an important role in defense against viral infections, and IDO1 is specifically
induced by IFNs, we investigated the response of BALB/c IDO1-KO mice to an infection with
MCMV. Brisse et al. showed that MCMV infection of WT mice represents a natural model of
Fig 2. Comparison between IDO1-KO and IFN-γ-KOmice after CFA injection.CFA was injected into BALB/cWT, IDO1-KO and IFN-γ-KO mice at day 0.
Mice were sacrificed at day 21 after immunization. A. Average ± SD percent body weight change. B. Spleen weight as a percentage of total body weight. C.
Blood platelet and neutrophil counts as measured by hematology analyzer. D. Percentage of live CD3- CD49b+ CD122+ natural killer cells of total live spleen
cells. B-D: Symbols represent individual mice with corresponding group median. Data from one experiment. NI, noninjected; CFA, complete Freund’s
adjuvant; NK, natural killer.
doi:10.1371/journal.pone.0150075.g002
IDO1 in Mouse Models of sJIA and sHLH
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virus-associated HLH as these mice displayed multiple features of HLH such as fever, cytope-
nia, hemophagocytosis, hyperferritinemia and elevated serum levels of sCD25, which were
accompanied by lymphadenopathy, coagulopathy, liver dysfunction and hypercytokinemia
[27]. Upon infection with MCMV, both WT and IDO1-KO mice showed severe wasting and
presented with fever at day 2 post-infection (Fig 4A and 4B). At day 5 post-infection, no change
in red blood cells was found, while blood platelets and lymphocytes were equally decreased in
WT and IDO1-KO mice (Fig 4C). Neutrophils were highly elevated after MCMV infection,
with no difference between WT and IDO1-KO mice (Fig 4C). As a measure of liver pathology,
levels of liver enzymes ALT and AST were found to be increased after MCMV infection in both
mouse strains (Fig 4D). Relative numbers of spleen NK cells were decreased, and plasma ferri-
tin and sCD25 levels were increased after MCMV infection without any significant differences
between WT and IDO1-KO mice (Fig 4E–4G). Although sCD25 levels were not significantly
different between MCMV-infected WT and IDO1-KO mice, we did observe a trend towards
Fig 3. CpG-induced MAS inWT and IDO1-KOmice.C57BL/6WT and IDO1-KOmice were repeatedly injected with PBS or CpG and were sacrificed at day
9. A+B. Spleen and liver weight as a percentage of total body weight.C-H. Red blood cell, platelet, lymphocyte, white blood cell, neutrophil, and monocyte
counts in whole blood as measured by hematology analyzer. I. NK cell numbers were determined as CD3-CD49b+CD122+ cells out of total live splenocytes.
A pool of splenocytes from 6–8 mice per group was analyzed. Symbols represent individual mice with the group median. Data from one experiment. *
p<0.05, ** p<0.01; Kruskal-Wallis with Dunn’s post test.
doi:10.1371/journal.pone.0150075.g003
IDO1 in Mouse Models of sJIA and sHLH
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Fig 4. MCMV infection in the absence of IDO1. BALB/cWT and IDO1-KOmice were infected with MCMV. Mice were sacrificed at day 5 post-infection. A.
Average percent weight change after infection.B. Rectal temperature at day 2 post-infection. C. Red blood cell, platelet, lymphocyte and neutrophil counts in
whole blood as measured by hematology analyzer.D.Measurement of alanine and aspartate transaminase (ALT/AST) levels in plasma. E. Percentage of
CD3-CD49b+CD122+ NK cells of live splenocytes. F. Plasma ferritin level.G. Plasma sCD25 level. Dotted line represents detection limit of the ELISA.
Symbols represent individual mice with corresponding group median. A. Representative image from 3–4 independent experiments. B-D. Data points from
2–3 independent experiments. E-G. Data from one experiment. * p<0.05, ** p<0.01, *** p<0.001; Kruskal-Wallis with Dunn’s post test. NI, not infected;
MCMV, mouse cytomegalovirus.
doi:10.1371/journal.pone.0150075.g004
IDO1 in Mouse Models of sJIA and sHLH
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higher levels of sCD25 in plasma of MCMV-infected IDO1-KO mice, which might suggest an
increased T cell activation in these mice. Nevertheless, as these minor differences did not affect
overall disease symptoms, we believe they are subordinate. We can conclude that similar to the
other mouse models, IDO1 does not play a role in an MCMV-triggered sHLH mouse model.
IDO1 does not affect cytokine production, number of regulatory T cells,
proliferation or apoptosis in T cell-triggered inflammation
Both sJIA and especially HLH/MAS are characterized by a cytokine storm [16,17]. Further-
more, HLH/MAS patients display an excessive proliferation of T cells [10,21]. As it is known
that IDO plays an important role in controlling excessive T cell proliferation, we wanted to
look into the role of IDO1 in a T cell-triggered cytokine release syndrome [25]. Hereto, BALB/
c WT and IDO1-KO mice were treated with anti-CD3 antibodies. Blood glucose levels were
decreased after anti-CD3 injection (Fig 5A). Injection of anti-CD3 resulted in an increased
weight of the spleen and inguinal lymph nodes of both WT and IDO1-KO mice (Fig 5B). Fur-
ther, anti-CD3 elicited a decrease in relative abundances of CD4+ and CD8+ T cells in the
inguinal lymph nodes (Fig 5C) and a decrease of immature CD4+CD8+ thymocytes, a well
described feature of the anti-CD3 cytokine release syndrome in mice (Fig 5D) [25]. The per-
centage of FOXP3+ Treg cells in the inguinal lymph nodes and the thymus was increased in
both WT and IDO1-KO mice after treatment with anti-CD3 (Fig 5E). Overall, no differences
were observed in IDO1-KO mice as compared to their WT counterparts. Next, serum cytokine
levels were analyzed 4h and 24h after anti-CD3 treatment. Anti-CD3 treatment increased
serum levels of Th1 cytokines IL-2, IFN-γ and TNF-α (Fig 6A) and Th2 cytokines IL-4, IL-5
(Fig 6B) to a similar extent in both WT and IDO1-KO mice. Other, more monocyte-related
cytokines IL-6 and IL-10, were similarly increased in IDO1-KO andWT mice, upon challenge
with anti-CD3 (Fig 6B). Except for IL-10, levels of most cytokines decreased after 24 hours (Fig
6A and 6B). To verify whether IDO1 affects T cell proliferation and apoptosis, we stained for
the proliferation marker KI67 and the apoptosis marker CASP3. In both lymph node and thy-
mus, we found no difference in the increase of apoptosis after anti-CD3 treatment between
WT and IDO1-KO mice (Fig 6C and 6D). There was an increase in proliferating lymph node
cells, while the percentage of proliferating thymus cells was decreased (Fig 6C and 6D). Again
no difference was found between WT and IDO1-KO animals. In conclusion, genetic ablation
of IDO1 does not influence cytokine production, numbers of Treg cells, proliferation or apo-
ptosis after anti-CD3 treatment.
No differences in IDO2 or TDO levels between wild-type mice and
IDO1-deficient mice
Aside from IDO1, IDO2 and TDO can catalyze degradation of Trp and might be capable of
compensating the loss of IDO1 in these mice. We therefore analyzed IDO2 and TDO2 mRNA
levels in liver of CpG-, MCMV- and anti-CD3-injected mice (Fig 7A). We did not observe
increased expression of IDO2 or TDO2 in IDO1-KO mice. IDO2 mRNA even showed a trend
towards lower levels in IDO1-deficient mice, which might potentially be linked to the genetic
interaction of IDO1 and IDO2 [32]. In addition, we analyzed the protein levels of IDO2 and
TDO by western blot in cell lysates of liver of WT and IDO1-KO C57BL/6 mice treated with
PBS or CpG. IDO2 was not detected (data not shown). TDO was expressed by liver cells with
similar levels in WT and IDO1-KO mice and CpG treatment decreased TDO expression (Fig
7B). We can conclude that the absence of IDO1 is not compensated by clear-cut increased
IDO2 or TDO2 expression.
IDO1 in Mouse Models of sJIA and sHLH
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Discussion
We previously reported a limited IFN-γ profile with low IDO activity in plasma of sJIA patients
and a significant IFN-γ-profile with highly raised IDO in HLH patients [20]. IFN-γ is a potent
inducer of IDO1 [6]. To investigate the immune-modulatory role of IDO1 in sJIA and sHLH,
we used 3 recently described animal models for sJIA and sHLH, in which a role of IFN-γ was
demonstrated by using specific neutralizing antibodies or IFN-γ gene-deficient mice [22,31].
In a CFA-injected mouse model, sJIA-like symptoms are elicited in IFN-γ-KO mice or in
WT mice injected with IFN-γ neutralizing antibodies, indicating IFN-γ provides protection in
the disease [22]. IFN-γ possesses both pro- and anti-inflammatory properties, with induction
of IDO1 as an example of the latter [33]. Amongst others, IDO can stimulate induction of Treg
cells, while it can inhibit Th17 cells. A Treg/Th17 imbalance has been suggested in sJIA [16],
Fig 5. Anti-CD3-induced cytokine release syndrome in BALB/cWT and IDO1-KOmice. BALB/c WT and IDO1-KOmice were treated with a single
injection of anti-CD3 or PBS, mice were monitored and sacrificed after 24h.A. Average ± SD blood glucose levels in mice at 0, 4, 8 and 24h post-injection. B.
Spleen and inguinal lymph nodes weight as a percentage of total body weight.C. Percentage of CD4+ and CD8+ T cells of total lymph node cells.D.
Percentage of CD4+CD8+ double positive T cells of total thymic cells. E. Percentages of CD4+CD25+FOXP3+ Treg cells of total lymph node and thymic cells.
B-E: Symbols represent individual mice with corresponding group median. Data from one experiment. * p<0.05, ** p<0.01; Kruskal-Wallis with Dunn’s post
test. aCD3, anti-CD3; LN, lymph node, Treg, regulatory T cells.
doi:10.1371/journal.pone.0150075.g005
IDO1 in Mouse Models of sJIA and sHLH
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Fig 6. IDO1 deficiency does not affect cytokine release, proliferation and apoptosis in anti-CD3-treated mice. A+B.In anti-CD3- and PBS-treated
BALB/cWT and IDO1-KOmice, serum Th1 cytokines (A) and Th2 and monocyte-related cytokines (B) were analyzed 4h and 24h post-injection. C+D.
Inguinal lymph node (C) and thymic (D) cells were stained for the apoptosis marker caspase 3 (CASP3) and a proliferation marker KI67. Percentages of
CASP3+ or KI67+ cells in total lymph node (C) and thymic (D) cells are shown. Symbols represent individual mice with corresponding group median. Data
from one experiment. * p<0.05, ** p<0.01; Kruskal-Wallis with Dunn’s post test. aCD3, anti-CD3; LN, lymph node.
doi:10.1371/journal.pone.0150075.g006
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Fig 7. Expression of IDO2 and TDO in liver of WT and IDO1-KOmice. A. Ido2 and Tdo2 expression was
assessed by qPCR in liver of CpG-, MCMV- and anti-CD3-injected mice. Expression levels were normalized
toGapdh (CpGmodel) orGapdh together withGusb (MCMV and anti-CD3model). * p<0.05; Kruskal Wallis
plus Dunn’s post test. NI, not infected; aCD3, anti-CD3. Data from one experiment.B.WT and IDO1-KO
C57BL/6 mice were repeatedly injected with PBS or CpG and TDO protein expression was measured by
western blot analysis in liver lysates at day 9 in 4 mice per group. Expression of β-actin was included as a
loading control.
doi:10.1371/journal.pone.0150075.g007
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and might thus be linked to the particularly low IDO activity in these patients. Nevertheless,
we did not find evidence for a role of IDO1 in the sJIA mouse model.
The role of IFN-γ in HLH/MAS seems different, as levels of IFN-γ and downstream proteins,
including IDO, are highly increased in HLH/MAS [20,34,35]. In mouse models of primary HLH
and in the CpG-triggered MAS model used in the current study, IFN-γ is pathogenic, as anti-
IFN-γ antibodies could ameliorate disease and relieved most symptoms [31,36,37]. In contrast,
in the MCMV-associated sHLHmodel described by Brisse et al., IFN-γ was protective [27].
Taken together, the data indicate that the role of IFN-γ in HLH and sJIA is complex and is most
likely related to its bivalent features, i.e. its pronounced pro- and anti-inflammatory activities. As
IDO has an important immune-modulatory function, one would expect an aggravation of dis-
ease in the absence of IDO. However, in both the CpG-triggered MAS model and the MCMV-
triggered sHLHmodel, no differences were observed betweenWT and IDO1-KOmice. As the
absence of IDO1 did not seem to influence disease in different inflammatory mouse models, we
investigated IDO1 expression inWTmice infected with MCMV and treated with CpG. In white
blood cells, spleen and liver, MCMV infection induced the expression of IDO1 mRNA (S1 Fig).
Similar data were obtained in liver of CpG-injected mice (S1 Fig). Thus, the lack of differences in
disease outcome between IDO1-KOmice andWT counterparts cannot be explained by the
absence of IDO induction in these sHLHmodels. We additionally measured IDO1 mRNA levels
in the sJIA mouse model. Although we found (not significantly) increased IDO1mRNA in
lymph nodes of CFA-injectedWT animals, IDO1 levels were decreased in spleen and liver of
these mice (S1 Fig). These relatively low levels of IDO1 are in line with the IDO activity we
found to be low in plasma of sJIA patients. In the anti-CD3model, IDO1 mRNA levels were not
increased (S1 Fig). For the anti-CD3 cytokine release model, we can therefore not exclude that a
lack of differences is simply caused by a lack of involvement of IDO1.
Although IDO is involved in inducing apoptosis, inhibiting T cell proliferation and promot-
ing Treg differentiation, we did not find differences in these features between WT and IDO1-
KOmice in a T cell-triggered cytokine release syndrome. Studies investigating the contribution
of IDO to Treg differentiation have predominantly been performed in vitro or ex vivo, using
Treg suppression assays. On the other hand, in vivo studies reported the abnormal differentia-
tion of antigen-specific Treg cells after mucosal antigen challenge [6]. Treg cells of anti-
CD3-challenged IDO1-KO mice might show decreased functionality in ex vivo suppression
assays. In addition, since the anti-CD3 model does not trigger T cells in an antigen-specific
matter, this might as well explain the lack of an observed difference in IDO1-KO mice.
IDO1 is believed to play an important role in acquired tolerance, nevertheless, IDO1-defi-
cient mice do not develop spontaneous lethal autoimmune disorders. However it was shown in
different ways that inhibiting IDO abrogates acquired immunity against new antigens, for
example in transplanted tissues [6]. IDO has been reported to be immunosuppressive in differ-
ent autoimmune models such as experimental autoimmune encephalomyelitis [38,39] and col-
lagen-induced arthritis [40,41], as demonstrated by using pharmacological inhibitors of IDO
[39,40] and by using IDO1-deficient mice [38,41]. With respect to systemic lupus erythemato-
sus, IDO1-KO mice that were chronically exposed to apoptotic cells developed a lupus-like
syndrome and pharmacological inhibition of IDO accelerated disease in the MRL-lpr mouse
model for spontaneous lupus [42]. Except for the anti-CD3-induced model, all disease models
in our study rely on an innate immune stimulus and all mouse models lack a specific antigenic
stimulus. Since the absence of IDO1 does not influence disease in any of the inflammatory
mouse models we described here, one could argue that IDO1 is important in autoimmune,
rather than in autoinflammatory disease.
IDO was initially described as an antimicrobial molecule. Multiple in vitro studies revealed
restricted replication of different intracellular pathogens, among which Toxoplasma gondii,
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Chlamydia species and viruses [6]. In vivo, Hoshi et al. reported a decreased viral replication
due to increased type I IFNs in IDO1-KO mice after infection with LP-BM5 murine leukemia
virus [43]. In our MCMV-associated sHLH mouse model, mice were sacrificed at day 5 post-
infection, and IDO1-KO mice had similar viral titers as compared to WT mice (S2 Fig). In con-
trast to the acute virus infection that is described in the current study, Hoshi et al. detected dif-
ferences in viral load at 8 weeks post-infection, suggesting IDO1 might play a role in the
chronic phase of infection. Interestingly, when looking at the in vivo effect of IDO1 by using
IDO1-deficient mice, Divanovic et al. reported genetic ablation of the IDO1 gene did not affect
Toxoplama gondii infection in mice, while pharmacologic inhibition of IDO led to increased
mortality and parasitic burden [44].
An explanation for the different results obtained with IDO1-KO mice as compared to those
using a pharmacological IDO inhibitor, may lie in the discovery of other enzymes catalyzing
the degradation of Trp and that are target of pharmacological inhibition. Before the discovery
of IDO2, most studies investigating the role of IDO used a pharmacological IDO inhibitor
1-methyl-Trp (1MT), a molecule blocking both the IDO1 and IDO2 enzyme. Moreover, IDO1
and IDO2 can genetically interact, instigating a critical role for IDO2 in IDO1-mediated T cell
regulation [32]. Although some studies reported IDO2 mRNA to be induced by IFN-γ as well,
this could not always be confirmed [8]. Additionally, TDO, which is mainly expressed in the
liver and less subjective to induction by inflammatory triggers, can also degrade Trp to Kyn
[1]. Since IDO1-deficiency does not affect disease in both sJIA and sHLH mouse models, we
hypothesized enzymatic activity of IDO2 and TDOmight compensate for the absence of
IDO1. In contrast to our previous study in patients with sJIA and HLH/MAS [20], we were not
able to measure IDO activity (e.g. Kyn/Trp ratios) in plasma of mice, due to borderline detec-
tion levels of Kyn. Nevertheless, Trp levels were detectable and were slightly but not signifi-
cantly decreased upon challenge with CpG, also in the absence of IDO1, suggesting
compensated tryptophan degradation in IDO1-KO mice (data not shown). Even though we
did not find increased expression of IDO2 or TDOmRNA nor protein levels in IDO1-KO
mice after repeated CpG injection or after MCMV infection, homeostatic levels of these
enzymes might already be sufficient to compensate for the loss of IDO1. Analysis of Kyn/Trp
levels in these mice could clarify these assumptions and treatment with 1MT could attribute a
role to both IDO1 and IDO2.
In conclusion, the absence of IDO1 does not affect disease in neither a CFA-elicited mouse
model for sJIA, a TLR9-triggered MAS model, an MCMV-associated sHLH model, nor in mice
with anti-CD3-elicited cytokine release syndrome. Although we could not detect increased
expression of two other Trp-degrading enzymes, IDO2 and TDO, we hypothesize that even
basal levels of these enzymes might compensate for the lack of IDO1 in these mice.
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